| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Patel S and Mishra BK | Oxidation of cholesterol by a biomimetic oxidant, cetyltrimethylammonium dichromate. | 2006 | J. Org. Chem. | pmid:16626135 |
| Gilliver SC et al. | Androgens modulate the inflammatory response during acute wound healing. | 2006 | J. Cell. Sci. | pmid:16449322 |
| Sobel V et al. | Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. | 2006 | J. Clin. Endocrinol. Metab. | pmid:16735493 |
| Woollett LA et al. | Micellar solubilisation of cholesterol is essential for absorption in humans. | 2006 | Gut | pmid:16407385 |
| Motola DL et al. | Identification of ligands for DAF-12 that govern dauer formation and reproduction in C. elegans. | 2006 | Cell | pmid:16529801 |
| Robaire B and Henderson NA | Actions of 5alpha-reductase inhibitors on the epididymis. | 2006 | Mol. Cell. Endocrinol. | pmid:16476520 |
| Stottrup BL and Keller SL | Phase behavior of lipid monolayers containing DPPC and cholesterol analogs. | 2006 | Biophys. J. | pmid:16461392 |
| Pitts WR | Re: The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. | 2006 | J. Urol. | pmid:16753453 |
| Frye SV | Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. | 2006 | Curr Top Med Chem | pmid:16719800 |
| Andriole GL et al. | Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. | 2006 | J. Urol. | pmid:16600723 |
| Dolder CR | Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia. | 2006 | Ann Pharmacother | pmid:16569804 |
| Tarter TH and Vaughan ED | Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia. | 2006 | Curr. Pharm. Des. | pmid:16515494 |
| Marszalek M and Madersbacher S | [Epidemiology of BPH and medication approaches]. | 2006 | Ther Umsch | pmid:16514964 |
| Fox SA et al. | Identifying putative contraceptive targets by dissecting signal transduction networks in the epididymis using an in vivo electroporation (electrotransfer) approach. | 2006 | Mol. Cell. Endocrinol. | pmid:16423449 |
| Dixon J et al. | Prolonged human chorionic gonadotrophin stimulation as a tool for investigating and managing undescended testes. | 2007 | Clin. Endocrinol. (Oxf) | pmid:17645564 |
| Thevis M et al. | Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite. | 2007 | Ther Drug Monit | pmid:17417080 |
| Petraki CD and Sfikas CP | Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. | 2007 | Histol. Histopathol. | pmid:17128417 |
| Bordet T et al. | Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. | 2007 | J. Pharmacol. Exp. Ther. | pmid:17496168 |
| Wheeler RE | Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate inflammation resolution to prostate cancer evolution). | 2007 | Clin Interv Aging | pmid:18044088 |
| Borst SE et al. | Anabolic effects of testosterone are preserved during inhibition of 5alpha-reductase. | 2007 | Am. J. Physiol. Endocrinol. Metab. | pmid:17488806 |
| Araki M et al. | Decreased efficiency of potassium-titanyl-phosphate laser photoselective vaporization prostatectomy with long-term 5 alpha-reductase inhibition therapy: is it true? | 2007 | Urology | pmid:18068449 |
| Hannemann F et al. | Biocatalytic synthesis of 4-pregnen-20,21-diol-3-one, a selective inhibitor of human 5alpha-reductase type II. | 2007 | J Enzyme Inhib Med Chem | pmid:18035825 |
| Andersson KE | LUTS treatment: future treatment options. | 2007 | Neurourol. Urodyn. | pmid:17696154 |
| Barat P et al. | Effects of gonadectomy on glucocorticoid metabolism in obese Zucker rats. | 2007 | Endocrinology | pmid:17628001 |
| Moinpour CM et al. | Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. | 2007 | J. Natl. Cancer Inst. | pmid:17596576 |
| Lunacek A et al. | Fetal distribution of 5alpha-reductase 1 and 5alpha-reductase 2, and their input on human prostate development. | 2007 | J. Urol. | pmid:17574609 |
| Kibel AS | Optimizing prostate biopsy techniques. | 2007 | J. Urol. | pmid:17509275 |
| Schmidt LJ et al. | Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. | 2007 | Prostate | pmid:17477363 |
| Prayer-Galetti T | Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. | 2007 | Eur. Urol. | pmid:17448594 |
| Yassin AA and Saad F | Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate. | 2007 | Andrologia | pmid:17714216 |
| Cussenot O et al. | Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. | 2007 | Eur. Urol. | pmid:17448593 |
| Maier C | Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. | 2007 | Eur. Urol. | pmid:17448591 |
| Morgentaler A | Re: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. | 2007 | J. Urol. | pmid:17437855 |
| Chai TC | Treatment of men with lower urinary tract symptoms and overactive bladder. | 2007 | JAMA | pmid:17374808 |
| GarcÃa CI et al. | Differential gene expression during development in two oligodendroglial cell lines overexpressing transferrin: a cDNA array analysis. | 2007 | Dev. Neurosci. | pmid:17119318 |
| Seiffert K et al. | Inhibition of 5alpha-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro. | 2007 | Horm. Metab. Res. | pmid:17326010 |
| Gooren LJ et al. | Decline of plasma 5alpha-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levels. | 2008 | Andrologia | pmid:18811920 |
| Kolasa A et al. | Expression of E-SOD, GPX5 mRNAs and immunoexpression of Cu/ZnSOD in epididymal epithelial cells of finasteride-treated rats. | 2008 | Andrologia | pmid:18811921 |
| Bordet T et al. | Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. | 2008 | J. Pharmacol. Exp. Ther. | pmid:18492948 |
| Amory JK et al. | The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. | 2008 | J. Urol. | pmid:18423697 |
| Tomlinson JW et al. | Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss. | 2008 | Diabetes | pmid:18340018 |
| Wilt TJ and N'Dow J | Benign prostatic hyperplasia. Part 2--management. | 2008 | BMJ | pmid:18219042 |
| Khan SA | Synthesis, characterization and in vitro antibacterial activity of new steroidal 5-en-3-oxazolo and thiazoloquinoxaline. | 2008 | Eur J Med Chem | pmid:18455270 |
| Carneiro MM et al. | Androgen receptor and 5alpha-reductase are expressed in pelvic endometriosis. | 2008 | BJOG | pmid:17983420 |
| Hadziselimovic F and Dessouky N | Differences in testicular development between 5alpha-reductase 2 deficiency and isolated bilateral cryptorchidism. | 2008 | J. Urol. | pmid:18639287 |
| Holzgrabe U and Sinz A | [Alpha blockers and 5-alpha reductase inhibitors]. | 2008 | Pharm Unserer Zeit | pmid:18615868 |
| Golbano JM et al. | Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. | 2008 | Int. J. Oncol. | pmid:18360719 |
| Faucher F et al. | The crystal structure of human Delta4-3-ketosteroid 5beta-reductase defines the functional role of the residues of the catalytic tetrad in the steroid double bond reduction mechanism. | 2008 | Biochemistry | pmid:18624455 |
| Ford MM et al. | Inhibition of 5alpha-reduced steroid biosynthesis impedes acquisition of ethanol drinking in male C57BL/6J mice. | 2008 | Alcohol. Clin. Exp. Res. | pmid:18565155 |
| Tomlinson JW et al. | Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. | 2008 | Diabetes | pmid:18633104 |
4-Cholesten-3-one
4-Cholesten-3-one is a lipid of Sterol Lipids (ST) class. 4-cholesten-3-one is associated with abnormalities such as Dehydration, Xanthomatosis, Cerebrotendinous, Peripheral Neuropathy, L.mexicana and Xanthoma. The involved functions are known as CYP27A1activity, 25-hydroxycholesterol 7alpha-hydroxylase activity, Biochemical Pathway, Anabolism and Oxidation. 4-cholesten-3-one often locates in Mitochondria, Liver, Body tissue, Hepatic, Mitochondria and Endothelium of artery. The associated genes with 4-Cholesten-3-one are P4HTM gene, tryptones and Regulon. The related lipids are Cholestenones, 7-hydroxy-4-cholesten-3-one, cholest-4-en-3-one, 25-hydroxycholesterol and 24-hydroxycholesterol.
Cross Reference
Introduction
To understand associated biological information of 4-Cholesten-3-one, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 4-Cholesten-3-one?
4-Cholesten-3-one is suspected in Dehydration, Xanthomatosis, Cerebrotendinous, Peripheral Neuropathy, L.mexicana, Xanthoma, Rare Diseases and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
No disease MeSH terms mapped to the current reference collection.
PubChem Associated disorders and diseases
What pathways are associated with 4-Cholesten-3-one
Lipid pathways are not clear in current pathway databases. We organized associated pathways with 4-Cholesten-3-one through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Related references are published most in these journals:
| Pathway name | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 4-Cholesten-3-one?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 4-Cholesten-3-one?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 4-Cholesten-3-one?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 4-Cholesten-3-one?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 4-Cholesten-3-one?
There are no associated biomedical information in the current reference collection.